Opportunity Information: Apply for RFA DE 12 011
Apply for RFA DE 12 011
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Molecular Characterization of Salivary Gland Tumors (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research.
- This funding opportunity was created on Jan 11, 2012 and posted on Jan 11, 2012.
- Applicants must submit their applications by Mar 19, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts State governments County governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities For profit organizations other than small businesses Special district governments Native American tribal governments (Federally recognized) Private institutions of higher education City or township governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Molecular Characterization of Salivary Gland Tumors (R01) funding opportunity (RFA-DE-12-011) is a National Institutes of Health grant announcement released by the National Institute of Dental and Craniofacial Research (NIDCR) to support research that advances both basic and translational understanding of salivary gland tumors. The main goal is to improve how these tumors are defined at the molecular level and to strengthen the experimental tools needed to study how they start, how they progress, and how they might respond to treatment. This is an R01 Research Project Grant mechanism, meaning it is intended for substantial, hypothesis-driven projects that can produce meaningful datasets, models, and insights that move the field forward.
The scientific focus is centered on two major, complementary areas. First, NIDCR is seeking studies that apply systematic, comprehensive, and data-rich "omics" approaches to salivary gland tumors in order to define their molecular signatures. In practice, this points to integrative profiling strategies such as genomics, transcriptomics, epigenomics, proteomics, metabolomics, and related computational analyses aimed at identifying tumor subtypes, pathways, driver alterations, biomarkers, or other distinguishing molecular patterns. The emphasis on "systematic" and "comprehensive" suggests interest in well-designed studies with strong data depth, careful annotation, and analytical rigor that can clarify how these tumors are categorized molecularly and how those categories might relate to behavior, prognosis, or therapeutic vulnerabilities.
Second, the FOA prioritizes the development of relevant mouse models that can be used to study tumor initiation and progression and to support preclinical testing of potential therapeutics. This area is aimed at building or refining in vivo systems that reflect the biology of salivary gland tumors with enough fidelity to be useful for mechanistic studies and for evaluating candidate treatments before moving toward clinical testing. This could include engineered mouse models or other approaches that enable researchers to track disease evolution, interrogate oncogenic mechanisms, and test interventions in a controlled and biologically meaningful setting.
From an administrative and eligibility standpoint, this is a discretionary grant in the health research domain (CFDA 93.121, Oral Diseases and Disorders Research) and it does not require cost sharing or matching. The announcement was posted on January 11, 2012, with an original and current closing date of March 19, 2012, and it was archived on April 19, 2012. Eligibility is broad and includes many types of U.S. organizations such as public and private institutions of higher education, nonprofits (including and not limited to 501(c)(3) organizations), small businesses, for-profit organizations (other than small businesses), and a wide range of government entities (state, county, city/township, special district), as well as tribal governments and tribally controlled institutions. The opportunity also explicitly allows participation by non-U.S. entities: foreign institutions may apply, non-U.S. components of U.S. organizations are eligible, and foreign components (as defined by NIH policy) are permitted, which opens the door to international collaboration and research sites when scientifically justified.
Applicants looking for the full details were directed to the NIH Grants Guide page for RFA-DE-12-011, and technical access issues were routed to the NIH Office of Extramural Research webmaster contact. Overall, the FOA is essentially a targeted NIH research call designed to accelerate molecular classification and model development for salivary gland tumors, with the broader intent of enabling better biological understanding and more credible preclinical therapeutic testing.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "Molecular Characterization of Salivary Gland Tumors (R01)" and is identified as RFA-DE-12-011.
Which agency is offering this grant?
This is a National Institutes of Health (NIH) grant announcement released by the National Institute of Dental and Craniofacial Research (NIDCR).
What type of grant mechanism is this?
This funding opportunity uses the R01 Research Project Grant mechanism, which is designed for substantial, hypothesis-driven research projects intended to generate meaningful datasets, models, and insights.
What is the overall purpose of the FOA?
The main purpose is to advance both basic and translational understanding of salivary gland tumors by improving how these tumors are defined at the molecular level and by strengthening experimental tools to study tumor initiation, progression, and potential treatment response.
What scientific areas does the FOA emphasize?
The FOA emphasizes two complementary areas: (1) systematic and comprehensive "omics" approaches to define molecular signatures of salivary gland tumors, and (2) development of relevant mouse models to study tumor initiation/progression and to support preclinical therapeutic testing.
What does "omics" mean in the context of this FOA?
Within this FOA, "omics" refers to integrative, data-rich molecular profiling strategies such as genomics, transcriptomics, epigenomics, proteomics, metabolomics, and related computational analyses aimed at identifying tumor subtypes, pathways, driver alterations, biomarkers, and other distinguishing molecular patterns.
What kinds of outcomes is the FOA trying to enable through molecular profiling?
Based on the description, the FOA is aiming to support work that clarifies molecular classification of salivary gland tumors and connects molecular categories to factors such as tumor behavior, prognosis, and potential therapeutic vulnerabilities.
What does the FOA mean by "systematic" and "comprehensive" studies?
The wording suggests interest in well-designed studies with strong data depth, careful annotation, and analytical rigor, rather than limited or narrowly scoped profiling efforts.
Does the FOA support research focused on biomarkers or tumor subtypes?
Yes. The FOA explicitly highlights identifying tumor subtypes, biomarkers, pathways, driver alterations, and other distinguishing molecular patterns as part of its molecular-signature goals.
What model development work is prioritized?
The FOA prioritizes developing relevant mouse models that reflect salivary gland tumor biology well enough to be useful for mechanistic studies of tumor initiation and progression and for preclinical testing of potential therapeutics.
How are the mouse models expected to be used?
The models are intended to enable researchers to track disease evolution, interrogate oncogenic mechanisms, and evaluate candidate interventions in a controlled in vivo setting before moving toward clinical testing.
Is this opportunity basic research, translational research, or both?
It is aimed at both basic and translational research, including molecular characterization (basic-to-translational) and model development intended to support preclinical therapeutic testing (translational).
What is the CFDA program associated with this opportunity?
The program is listed under CFDA 93.121, "Oral Diseases and Disorders Research."
Is cost sharing or matching required?
No. The opportunity explicitly states that it does not require cost sharing or matching.
When was the announcement posted?
The announcement was posted on January 11, 2012.
What was the closing date for applications?
The original and current closing date listed is March 19, 2012.
Is this funding opportunity still active?
No. It was archived on April 19, 2012.
What types of U.S. organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofits (including and not limited to 501(c)(3) organizations), small businesses, for-profit organizations (other than small businesses), and many government entities (state, county, city/township, special district), as well as tribal governments and tribally controlled institutions.
Can for-profit organizations apply?
Yes. The eligibility description includes for-profit organizations (other than small businesses) and also separately includes small businesses.
Are tribal entities eligible?
Yes. Tribal governments and tribally controlled institutions are explicitly included as eligible applicants.
Are foreign (non-U.S.) institutions eligible to apply?
Yes. The opportunity explicitly allows participation by non-U.S. entities, including foreign institutions applying directly.
Can a U.S. organization include non-U.S. components in the project?
Yes. Non-U.S. components of U.S. organizations are described as eligible.
Are "foreign components" allowed under NIH policy?
Yes. The opportunity states that foreign components (as defined by NIH policy) are permitted, supporting international collaboration or research sites when scientifically justified.
Where were applicants directed to find the full official details?
Applicants were directed to the NIH Grants Guide page for RFA-DE-12-011 for full details.
Where were technical access issues directed?
Technical access issues were routed to the NIH Office of Extramural Research (OER) webmaster contact.
In one sentence, what is this FOA trying to accelerate?
It is a targeted NIH research call intended to accelerate molecular classification of salivary gland tumors and the development of credible mouse models to enable stronger biological understanding and more meaningful preclinical therapeutic testing.
Browse more opportunities from the same category: Health
Next opportunity: BioWatch Program Field Operations Sample Collection Activities
Previous opportunity: Molecular Characterization of Salivary Gland Tumors (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DE 12 011
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DE 12 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| Conducting Research on Moderate Acute Malnutrition in Humanitarian Emergencies Apply for RFA GH 12 006 Funding Number: RFA GH 12 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Service Area Competition Additional Area (SAC AA) (Anchorage, AK) Apply for HRSA 12 169 Funding Number: HRSA 12 169 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Dental Reimbursement Program Apply for HRSA 12 080 Funding Number: HRSA 12 080 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Biodemography of Aging (R21) Apply for PAR 12 079 Funding Number: PAR 12 079 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Biodemography of Aging (R01) Apply for PAR 12 078 Funding Number: PAR 12 078 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biodemography of Aging (R03) Apply for PAR 12 080 Funding Number: PAR 12 080 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Leadership Group for a Clinical Research Network on Antibacterial Resistance (UM1) Apply for RFA AI 12 019 Funding Number: RFA AI 12 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Institutional Center Core Grants to Support Neuroscience Research (P30) Apply for PAR 12 081 Funding Number: PAR 12 081 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Maternal, Infant, and Early Childhood Home Visiting Research Program Apply for HRSA 12 159 Funding Number: HRSA 12 159 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Newborn Screening Technical Assistance and Data Repository Program Apply for HRSA 12 070 Funding Number: HRSA 12 070 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Health Strategic Information (SI) Apply for APS656 12 000004 Funding Number: APS656 12 000004 Agency: Mozambique USAID Maputo Category: Health Funding Amount: $300,000 |
| Surveillance Program Announcement Behavioral Risk Factor Surveillance System, Apply for CDC RFA SO 11 110202CONT12 Funding Number: CDC RFA SO 11 110202CONT12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Surveillance Program Announcement Behavioral Risk Factor Surveillance System, Apply for CDC RFA SO 11 110102CONT12 Funding Number: CDC RFA SO 11 110102CONT12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Announcement of a Limited Competition for the Continuation of the Cooperative Agreement on the Interaction of HIV Infection and Alcohol Abuse on Central Nervous System Morbidity (U01) Apply for RFA AA 12 011 Funding Number: RFA AA 12 011 Agency: National Institutes of Health Category: Health Funding Amount: $810,000 |
| Excellence in Hemoglobinopathies Research Award (EHRA) (U54) Apply for RFA HL 13 005 Funding Number: RFA HL 13 005 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Summer Institute for Training in Biostatistics II (T15) Apply for RFA HL 13 015 Funding Number: RFA HL 13 015 Agency: National Institutes of Health Category: Health Funding Amount: $248,000 |
| Stamping Out and Preventing Gender Based Violence (STOP GBV) Prevention and Advocacy Program Apply for SOL 611 12 000002 Funding Number: SOL 611 12 000002 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $5,000,000 |
| Stamping Out and Preventing Gender Based Violence (STOP GBV) Access to Justice Program Apply for SOL 611 12 000003 Funding Number: SOL 611 12 000003 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $3,300,000 |
| Stamping Out and Preventing Gender Based Violence (STOP GBV) Survivor Support Program Apply for SOL 611 12 000004 Funding Number: SOL 611 12 000004 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $7,900,000 |
| Increasing the Capacity of the Government of the Commonwealth of Dominica to Expand Coordinated HIV Prevention, Strategic Information, and Laboratory Programs under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1203 Funding Number: CDC RFA GH12 1203 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DE 12 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.